SecBot SecBot
8-K ·Filed Nov 12, 2026

VOR

Vor Biopharma Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 19h ago SEC0001193125-26-456955
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

Monitor IND filing for RC298 in H1 2027 and any progress in telitacicept Phase 3 trials. The $150M ATM facility and warrant dilution create overhang; watch for any ATM usage or warrant exercises.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

VOR drug pipeline →

telitacicept

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (global); Approved in China (SLE, IgAN, SjD)
Time to market
Telitacicept is already marketed in China for SLE. For US/EU approval, the earliest potential timeline depends on the global Phase 3 UPSTREAM MG readout (1H 2027) followed by BLA submissions, with potential approval possibly in 2028-2029 if results are positive.
Next catalyst
None dated

What to watchThe next major catalyst is the topline readout from the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, expected in the first half of 2027. Positive data would support US/EU regulatory filings and validate Vor Bio's strategy of replicating RemeGen's Chinese clinical success globally. Negative or mixed results would severely damage the thesis, as telitacicept is Vor Bio's lead asset. Also watch for enrollment completion updates from the UPSTREAM SjD Phase 3 trial in Sjogren's disease.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$19.32
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.52%
T+1 · $19.42
Vs SPY
+0.88%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $19.32entry
  2. T+1 · 4d ago +0.52%α +0.88% · $19.42
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vor Biopharma expanded its license agreement with RemeGen to include RC298, a next-generation dual BAFF/APRIL inhibitor, for development outside Greater China. Vor Bio paid $10M cash and issued a pre-funded warrant for 2.3M shares (valued at ~$46M) as upfront consideration, with up to $300M in additional development milestones. The deal strengthens Vor Bio's autoimmune pipeline but adds dilution and cash outlay.

Key Financial Metrics

Deal Type
license

Key Facts

  • Vor Bio and RemeGen entered an amended license agreement adding RC298, a next-gen dual BAFF/APRIL inhibitor, to the existing telitacicept franchise.
  • Upfront consideration: $10M cash + pre-funded warrant to purchase 2.3M shares at $0.0001/share (~$46M value based on Nov 11 closing price).
  • RemeGen eligible for up to $300M in development milestones, including $20M for initial clinical/tech transfer milestones.
  • Existing sales milestone and royalty framework (high single-digit to mid-teen % royalties) applies on an aggregated basis.
  • RC298 is in IND-enabling development; IND submission in China expected H1 2027.
  • Vor Bio reaffirmed cash runway into early 2029.
  • The warrant is subject to a 9.99% beneficial ownership limitation (can be increased to 19.99% with 61 days' notice).
  • Registration rights agreement requires filing a resale registration statement within 30 days, with liquidated damages for delays (up to $2.25M cap).
  • Cross-filing context: a 424B5 filed 13 days prior established a $150M ATM facility, adding potential future dilution capacity.

Financial Impact

$56M total upfront ($10M cash + ~$46M warrant value); up to $300M in development milestones; existing royalty framework applies

cashdilutionmilestone payments

Risk Factors

  • Dilution from 2.3M warrant shares (exercisable at $0.0001) and potential ATM sales under the $150M facility.
  • RC298 is preclinical; clinical failure or regulatory delays could impair the deal's value.
  • Reliance on RemeGen for preclinical and Phase 1 development in China; data may not be accepted by FDA/EMA.
  • Cash runway into early 2029 assumes no unexpected costs; additional capital may be needed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-456955
Document: vor-ex10_3.htm0001193125-26-456955
Document: vor-ex10_1.htm0001193125-26-456955
Document: vor-20261111.htm0001193125-26-456955
Document: vor-ex99_1.htm0001193125-26-456955
Document: 0001193125-26-456955-index-headers.html0001193125-26-456955
Document: 0001193125-26-456955-index.html0001193125-26-456955
Document: 0001193125-26-456955.txt0001193125-26-456955

Track record

17 reports on VOR

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
  2. Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
  4. Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
  5. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
  6. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
  7. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
  9. Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
  10. Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026